Login
Super Investors Invesco Discovery Fund

Invesco Discovery Fund

Aim Counselor Series Trust (invesco Counselor Series Trust) · net assets $7.41B · 101 holdings as of August 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.

Asset mix

EC: 97.1% · STIV: 2.9%

Financial position

Total assets
$7.53B
Total liabilities
$117M
Net assets
$7.41B
Assets attributable to miscellaneous securities
$0
Assets invested in controlled foreign corporations
$0
Borrowings payable within one year
$0
Payable to controlled companies within one year
$0
Payable to other affiliates within one year
$0
Other liabilities payable within one year
$0
Borrowings payable after one year
$0
Payable to controlled companies after one year
$0
Payable to other affiliates after one year
$0
Other liabilities payable after one year
$0
Payables for delayed-delivery investments
$0
Payables for standby commitments
$0
Liquidation preference of outstanding preferred stock
$0
Cash not reported in Parts C or D
$1M

Monthly flows and gains

Month 1 Month 2 Month 3
Sales $184M $162M $185M
Reinvestment $0 $668 $0
Redemptions $155M $141M $110M
Net realized gain (non-derivative) $538M $260M $29.4M
Net unrealized appreciation (non-derivative) $52M -$1.36B -$58.1M

The three months of the reporting period, as filed; month 3 ends August 31, 2026.

Filing details

Registrant
Aim Counselor Series Trust (invesco Counselor Series Trust)
Registrant CIK
1112996
Registrant LEI
LZYC3CZ7P12IRF1LLV60
Series
Invesco Discovery Fund
Series ID
S000064618
Series LEI
54930080U1BOE8PTXC74
SEC file number
811-09913
Address
11 Greenway Plaza, Suite 1000, Houston, US-TX, 77046-1173, US
Phone
800-959-4246
Form
NPORT-P
Filed
October 30, 2026
Report period ends
August 31, 2026
Report month ends
August 31, 2026
Accession number
000111299626000410
Holding Value % of net assets
Ligand Pharmaceuticals Inc. EC $180M 2.43%
Brightspring Health Services, Inc. EC $173M 2.34%
Jfrog Ltd. EC $171M 2.30%
Guardant Health, Inc. EC $155M 2.09%
Repligen Corp. EC $148M 2.00%
Halozyme Therapeutics, Inc. EC $147M 1.99%
Sanmina Corp. EC $141M 1.90%
Chord Energy Corp. EC $140M 1.89%
Enova International, Inc. EC $137M 1.84%
Wisdomtree, Inc. EC $123M 1.65%
Littelfuse, Inc. EC $121M 1.63%
Knight-swift Transportation Holdings Inc. EC $121M 1.63%
Onto Innovation Inc. EC $120M 1.62%
Cognex Corp. EC $120M 1.61%
Protagonist Therapeutics, Inc. EC $119M 1.61%
Ttm Technologies, Inc. EC $119M 1.60%
Five Below, Inc. EC $116M 1.57%
Twist Bioscience Corp. EC $116M 1.57%
Mercury Systems, Inc. EC $112M 1.51%
Vse Corp. EC $109M 1.47%
Viavi Solutions Inc. EC $109M 1.47%
Lattice Semiconductor Corp. EC $108M 1.46%
Axsome Therapeutics, Inc. EC $106M 1.43%
Bridgebio Pharma, Inc. EC $106M 1.42%
Sitime Corp. EC $105M 1.42%
Esco Technologies Inc. EC $102M 1.38%
Allegro Microsystems, Inc. EC $101M 1.36%
Semtech Corp. EC $101M 1.36%
Everus Construction Group, Inc. EC $99.7M 1.35%
Spx Technologies, Inc. EC $98.4M 1.33%
Nova Ltd. EC $97.6M 1.32%
Marex Group Ltd. EC $95.8M 1.29%
Manhattan Associates, Inc. EC $93.9M 1.27%
Ameris Bancorp EC $92.5M 1.25%
Enpro Inc. EC $84.7M 1.14%
Invesco Private Prime Fund STIV $82.8M 1.12%
Dave Inc. EC $82.7M 1.12%
Arcbest Corp. EC $81.9M 1.10%
Garrett Motion Inc. EC $81.8M 1.10%
Azz Inc. EC $81.2M 1.10%
Silicon Motion Technology Corp. EC $80.7M 1.09%
Ero Copper Corp. EC $78.6M 1.06%
Terawulf Inc. EC $77.8M 1.05%
Arrowhead Pharmaceuticals, Inc. EC $77.4M 1.04%
Acadian Asset Management Inc. EC $76.5M 1.03%
Glaukos Corp. EC $76.2M 1.03%
Madrigal Pharmaceuticals, Inc. EC $71M 0.96%
Forgent Power Solutions, Inc. EC $70.8M 0.96%
Argan, Inc. EC $68.8M 0.93%
Xometry, Inc. EC $68.4M 0.92%
Radnet, Inc. EC $68M 0.92%
Ati Inc. EC $66.3M 0.89%
Invesco Treasury Portfolio STIV $65.7M 0.89%
Embraer S.a. EC $65.6M 0.88%
Heartflow, Inc. EC $64.3M 0.87%
Golar Lng Ltd. EC $61.3M 0.83%
Hanover Insurance Group, Inc. (the) EC $59.9M 0.81%
Sterling Infrastructure, Inc. EC $58.3M 0.79%
Life Time Group Holdings, Inc. EC $58.1M 0.78%
Rush Street Interactive, Inc. EC $57.2M 0.77%

Showing top 60 of 101 holdings.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support